非酒精性脂肪性肝病与心血管疾病风险增加:临床关联、病理生理机制与药物影响
该叙述性综述概述了NAFLD与心血管、心脏及心律失常并发症风险增加之间的关联证据,探讨了将NAFLD与CVD联系起来的可能病理生理机制,并总结了当前NAFLD药物治疗对心血管风险的可能获益或不利影响。
要点
- NAFLD患者主要死因为心血管疾病,其次为肝外恶性肿瘤和肝脏相关并发症。
- NAFLD与主要心血管事件及其他心脏并发症风险增加独立相关。
- 当前NAFLD药物治疗可能对心血管风险产生获益或不利影响。
核心结论
- NAFLD尤其晚期形式与全因死亡风险增高相关,主要死因为心血管疾病。
- NAFLD与主要心血管事件及其他心脏并发症风险增加独立相关。
研究设计与样本
- 叙述性综述,总结关于NAFLD与心血管、心脏及心律失常并发症关联的文献。
主要发现
- 多项队列研究一致记录NAFLD尤其晚期形式与全因死亡风险增高相关。
- NAFLD患者主要死因为心血管疾病,其次为肝外恶性肿瘤和肝脏相关并发症。
- 越来越多证据表明NAFLD与主要心血管事件及其他心脏并发症风险增加独立相关。
临床怎么用
- 应关注NAFLD患者的心血管风险评估与管理。
- 选择NAFLD药物治疗时需考虑对心血管风险的可能影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of the world's adult population. Several cohort studies have consistently documented that NAFLD (especially in its more advanced forms) is associated with a higher risk of all-cause mortality and that the leading causes of death among patients with NAFLD are cardiovascular diseases (CVDs), followed by extrahepatic malignancies and liver-related complications. A growing body of evidence also indicates that NAFLD is strongly associated with an increased risk of major CVD events and other cardiac complications (ie, cardiomyopathy, cardiac valvular calcification and cardiac arrhythmias), independently of traditional cardiovascular risk factors. This narrative review provides an overview of the literature on: (1) the evidence for an association between NAFLD and increased risk of cardiovascular, cardiac and arrhythmic complications, (2) the putative pathophysiological mechanisms linking NAFLD to CVD and other cardiac complications and (3) the current pharmacological treatments for NAFLD that might also benefit or adversely affect risk of CVD.
引用
- Targher G, Byrne CD, Tilg H, et al. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020. PMID: 32321858. doi:10.1136/gutjnl-2020-320622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。